Publications & Presentations

Presentations

NGM282 Improves Fibrosis and NASH-Related Histology in 12 Weeks in Patients With Biopsy-Confirmed NASH, Which is Preceded By Significant Decreases in Hepatic Steatosis, Liver Transaminases and Fibrosis Markers at 6 Weeks (pdf)
EASL International Liver Congress, Paris, France, 14 April 2018


Publications

LEAP2 Is an Endogenous Antagonist of the Ghrelin Receptor
Cell Metabolism, 2017

Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15
Nature, 2017

Apelin-36 Modulates Blood Glucose and Body Weight Independently of Canonical APJ Receptor Signaling
Journal of Biological Chemistry, 2016

Restoration of euglycemia after duodenal bypass surgery is reliant on central and peripheral inputs in Zucker fa/fa rats
Diabetes Journals, 2013

NGM282

Effects of NGM282, an FGF19 variant, on colonic transit and bowel function in functional constipation: a randomized phase 2 trial (pdf)
The American Journal of Gastroenterology, 2018

NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial (pdf)
The Lancet, 2018

Engineered FGF19 Eliminates Bile Acid Toxicity and Lipotoxicity Leading to Resolution of Steatohepatitis and Fibrosis in Mice (pdf)
Hepatology Communications, 2017

Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis
Nature Communications, 2017

Mice Species-specific Control of Hepatocarcinogenesis and Metabolism by FGF19/FGF15
Journal of Hepatology, 2017

Engineered Fibroblast Growth Factor 19 Reduces Liver Injury and Resolves Sclerosing Cholangitis in Mdr2-Deficient Mice
Hepatology, 2016

Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19
Cancer Research, 2014

A nontumorigenic Variant of FGF19 Treats Cholestatic Liver Diseases
Science Translational Medicine, 2014